Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

SKYE

Skye Bioscience Inc

May 24 • 04:00PM ET

12.06

Dollar change +0.10
Percentage change 0.84	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: YOLO HRTS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.50	Insider Own	55.18%	Shs Outstand	28.07M	Perf Week	0.08%
Market Cap	338.52M	Forward P/E	-	EPS next Y	-1.40	Insider Trans	0.00%	Shs Float	12.58M	Perf Month	-6.15%
Income	-37.50M	PEG	-	EPS next Q	-0.17	Inst Own	9.28%	Short Float	0.88%	Perf Quarter	47.16%
Sales	0.00M	P/S	-	EPS this Y	79.40%	Inst Trans	-	Short Ratio	2.08	Perf Half Y	693.42%
Book/sh	2.81	P/B	4.29	EPS next Y	-26.20%	ROA	-75.43%	Short Interest	0.11M	Perf Year	254.71%
Cash/sh	3.29	P/C	3.66	EPS next 5Y	-	ROE	-101.20%	52W Range	1.44 - 19.41	Perf YTD	343.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.94%	ROI	-47.44%	52W High	-37.87%	Beta	1.64
Dividend TTM	-	Quick Ratio	5.99	Sales past 5Y	0.00%	Gross Margin	-	52W Low	737.50%	ATR (14)	1.02
Dividend Ex-Date	-	Current Ratio	5.99	EPS Y/Y TTM	47.70%	Oper. Margin	0.00%	RSI (14)	45.93	Volatility	5.46% 6.54%
Employees	11	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	86.94%	Payout	-	Rel Volume	0.81	Prev Close	11.96
Sales Surprise	-	EPS Surprise	1.08%	Sales Q/Q	-	Earnings	-	Avg Volume	53.22K	Price	12.06
SMA20	-2.65%	SMA50	-7.06%	SMA200	92.25%	Trades		Volume	42,933	Change	0.84%

Date	Action	Analyst	Rating Change	Price Target Change
May-23-24	Initiated	Cantor Fitzgerald	Overweight	$21
Apr-12-24	Initiated	Oppenheimer	Outperform	$25

May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-10-24 07:00AM	Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting (GlobeNewswire) -6.21%
May-07-24 11:59AM	Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program (News Direct)
Apr-30-24 07:00AM	Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting (GlobeNewswire)
Apr-23-24 07:00AM	Skye Bioscience to Present at Upcoming Investment Conferences (GlobeNewswire) -5.27%
08:00AM	Loading…
Apr-10-24 08:00AM	Skye Bioscience Uplists to The Nasdaq Global Market (GlobeNewswire) +39.69%
Mar-11-24 09:20AM	Skye Bioscience Announces $40 Million Private Placement Equity Financing (Newsfile) -24.95%
Mar-04-24 07:00AM	Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors (GlobeNewswire) +7.59%
Feb-26-24 07:00AM	Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension (GlobeNewswire) +13.82%
Feb-07-24 07:00AM	Skye Bioscience to Present at Oppenheimer Investor Conference (Newsfile) -7.55%
Jan-29-24 08:00AM	Skye Bioscience Announces $50.25 Million Private Placement Equity Financing (Newsfile) +29.03%

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SKYE

Skye Bioscience Inc

Upgrade your FINVIZ experience